IL-17 Targeted Drugs Signal Hope for Hidradenitis Suppurativa Patients
Dermatologist Thrasyvoulos Tzellos discussed exciting advancements in the treatment of Hidradenitis Suppurativa at the EADV congress. New drugs targeting IL-17, such as secukinumab, Bimekizumab and upatacitinib, show very promise in managing inflammation and draining fistulas, surpassing previous anti-TNF treatments.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
